Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with their use. Therefore, safer approaches are needed. CD6, expressed by T-lymphocyte...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurrea-Rubio, Mikel, Wu, Qi, Amin, M. Asif, Tsou, Pei-Suen, Campbell, Phillip L., Amarista, Camila E., Ikari, Yuzo, Brodie, William D., Mattichak, Megan N., Muraoka, Sei, Randon, Peggy M., Lind, Matthew E., Ruth, Jeffrey H., Mao-Draayer, Yang, Ding, Shengli, Shen, Xiling, Cooney, Laura A., Lin, Feng, Fox, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602169/
https://www.ncbi.nlm.nih.gov/pubmed/37886483
http://dx.doi.org/10.21203/rs.3.rs-3405677/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602169/
https://www.ncbi.nlm.nih.gov/pubmed/37886483
http://dx.doi.org/10.21203/rs.3.rs-3405677/v1

Ejemplares similares